|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: BLMH |
Gene summary for BLMH |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | BLMH | Gene ID | 642 |
| Gene name | bleomycin hydrolase | |
| Gene Alias | BH | |
| Cytomap | 17q11.2 | |
| Gene Type | protein-coding | GO ID | GO:0000096 | UniProtAcc | Q13867 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 642 | BLMH | LZE4T | Human | Esophagus | ESCC | 8.27e-15 | 5.43e-01 | 0.0811 |
| 642 | BLMH | LZE5T | Human | Esophagus | ESCC | 1.65e-02 | 4.83e-01 | 0.0514 |
| 642 | BLMH | LZE7T | Human | Esophagus | ESCC | 5.32e-05 | 2.81e-01 | 0.0667 |
| 642 | BLMH | LZE24T | Human | Esophagus | ESCC | 3.78e-12 | 3.36e-01 | 0.0596 |
| 642 | BLMH | LZE6T | Human | Esophagus | ESCC | 1.55e-04 | 1.94e-01 | 0.0845 |
| 642 | BLMH | P2T-E | Human | Esophagus | ESCC | 2.52e-23 | 5.38e-01 | 0.1177 |
| 642 | BLMH | P4T-E | Human | Esophagus | ESCC | 5.67e-35 | 8.21e-01 | 0.1323 |
| 642 | BLMH | P5T-E | Human | Esophagus | ESCC | 7.47e-07 | 3.76e-02 | 0.1327 |
| 642 | BLMH | P8T-E | Human | Esophagus | ESCC | 1.07e-11 | 8.12e-02 | 0.0889 |
| 642 | BLMH | P9T-E | Human | Esophagus | ESCC | 2.29e-17 | 4.40e-01 | 0.1131 |
| 642 | BLMH | P10T-E | Human | Esophagus | ESCC | 8.09e-13 | 4.81e-01 | 0.116 |
| 642 | BLMH | P11T-E | Human | Esophagus | ESCC | 8.07e-16 | 6.35e-01 | 0.1426 |
| 642 | BLMH | P12T-E | Human | Esophagus | ESCC | 5.71e-28 | 8.07e-01 | 0.1122 |
| 642 | BLMH | P15T-E | Human | Esophagus | ESCC | 7.29e-37 | 8.88e-01 | 0.1149 |
| 642 | BLMH | P16T-E | Human | Esophagus | ESCC | 6.28e-20 | 3.84e-01 | 0.1153 |
| 642 | BLMH | P17T-E | Human | Esophagus | ESCC | 6.18e-03 | 1.36e-01 | 0.1278 |
| 642 | BLMH | P19T-E | Human | Esophagus | ESCC | 4.84e-07 | 6.88e-01 | 0.1662 |
| 642 | BLMH | P20T-E | Human | Esophagus | ESCC | 7.34e-16 | 3.25e-01 | 0.1124 |
| 642 | BLMH | P21T-E | Human | Esophagus | ESCC | 1.80e-16 | 5.78e-01 | 0.1617 |
| 642 | BLMH | P22T-E | Human | Esophagus | ESCC | 6.54e-44 | 9.70e-01 | 0.1236 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000020917 | Esophagus | ESCC | protein polyubiquitination | 170/8552 | 236/18723 | 1.40e-16 | 1.09e-14 | 170 |
| GO:00067906 | Esophagus | ESCC | sulfur compound metabolic process | 201/8552 | 339/18723 | 2.64e-07 | 3.94e-06 | 201 |
| GO:000941020 | Esophagus | ESCC | response to xenobiotic stimulus | 253/8552 | 462/18723 | 4.55e-05 | 3.58e-04 | 253 |
| GO:000963620 | Esophagus | ESCC | response to toxic substance | 150/8552 | 262/18723 | 1.00e-04 | 7.12e-04 | 150 |
| GO:00442827 | Esophagus | ESCC | small molecule catabolic process | 201/8552 | 376/18723 | 1.35e-03 | 6.41e-03 | 201 |
| GO:000679021 | Liver | HCC | sulfur compound metabolic process | 212/7958 | 339/18723 | 5.60e-14 | 3.39e-12 | 212 |
| GO:004428221 | Liver | HCC | small molecule catabolic process | 225/7958 | 376/18723 | 6.50e-12 | 2.80e-10 | 225 |
| GO:000020921 | Liver | HCC | protein polyubiquitination | 151/7958 | 236/18723 | 1.90e-11 | 7.59e-10 | 151 |
| GO:001605421 | Liver | HCC | organic acid catabolic process | 152/7958 | 240/18723 | 5.11e-11 | 1.92e-09 | 152 |
| GO:00463952 | Liver | HCC | carboxylic acid catabolic process | 149/7958 | 236/18723 | 1.11e-10 | 3.87e-09 | 149 |
| GO:19016052 | Liver | HCC | alpha-amino acid metabolic process | 124/7958 | 195/18723 | 2.07e-09 | 5.79e-08 | 124 |
| GO:00065202 | Liver | HCC | cellular amino acid metabolic process | 167/7958 | 284/18723 | 1.91e-08 | 4.56e-07 | 167 |
| GO:000963622 | Liver | HCC | response to toxic substance | 153/7958 | 262/18723 | 1.37e-07 | 2.58e-06 | 153 |
| GO:00000962 | Liver | HCC | sulfur amino acid metabolic process | 29/7958 | 34/18723 | 3.26e-07 | 5.62e-06 | 29 |
| GO:000941022 | Liver | HCC | response to xenobiotic stimulus | 248/7958 | 462/18723 | 6.47e-07 | 1.02e-05 | 248 |
| GO:00090632 | Liver | HCC | cellular amino acid catabolic process | 70/7958 | 110/18723 | 6.12e-06 | 7.52e-05 | 70 |
| GO:19016062 | Liver | HCC | alpha-amino acid catabolic process | 53/7958 | 87/18723 | 4.01e-04 | 2.71e-03 | 53 |
| GO:0050667 | Liver | HCC | homocysteine metabolic process | 11/7958 | 14/18723 | 6.81e-03 | 2.73e-02 | 11 |
| GO:000020910 | Oral cavity | OSCC | protein polyubiquitination | 150/7305 | 236/18723 | 1.59e-14 | 9.27e-13 | 150 |
| GO:000963618 | Oral cavity | OSCC | response to toxic substance | 137/7305 | 262/18723 | 7.94e-06 | 8.52e-05 | 137 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| BLMH | SNV | Missense_Mutation | rs768600658 | c.398N>G | p.Val133Gly | p.V133G | Q13867 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-A2-A1G0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD |
| BLMH | SNV | Missense_Mutation | c.893N>A | p.Thr298Asn | p.T298N | Q13867 | protein_coding | deleterious(0.01) | possibly_damaging(0.617) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| BLMH | SNV | Missense_Mutation | rs768600658 | c.398N>G | p.Val133Gly | p.V133G | Q13867 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-B6-A1KF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| BLMH | SNV | Missense_Mutation | rs768600658 | c.398N>G | p.Val133Gly | p.V133G | Q13867 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-E2-A1LB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
| BLMH | insertion | Frame_Shift_Ins | novel | c.77_78insGTCTTGGAGA | p.Ala27SerfsTer70 | p.A27Sfs*70 | Q13867 | protein_coding | TCGA-B6-A0RG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| BLMH | SNV | Missense_Mutation | novel | c.1298N>C | p.Val433Ala | p.V433A | Q13867 | protein_coding | deleterious(0.01) | possibly_damaging(0.891) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| BLMH | SNV | Missense_Mutation | novel | c.44N>C | p.Ile15Thr | p.I15T | Q13867 | protein_coding | tolerated(0.76) | benign(0) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| BLMH | SNV | Missense_Mutation | novel | c.766N>A | p.Glu256Lys | p.E256K | Q13867 | protein_coding | tolerated(0.75) | benign(0.001) | TCGA-DG-A2KK-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| BLMH | SNV | Missense_Mutation | novel | c.800N>C | p.Lys267Thr | p.K267T | Q13867 | protein_coding | tolerated(0.06) | probably_damaging(0.999) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| BLMH | SNV | Missense_Mutation | novel | c.834N>G | p.His278Gln | p.H278Q | Q13867 | protein_coding | deleterious(0.01) | benign(0.084) | TCGA-PN-A8MA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |